Blood biomarker identified that predicts type 2 diabetes many years before diagnosis
An AI-based diagnostic tool is being developed through a biotech startup
A large study led by Lund University in Sweden has identified a protein in the blood that could predict type 2 diabetes up to nineteen years before the onset of the disease. The study is published in Nature Communications.

Symbolic image
pixabay.com
Type 2 diabetes is a growing global epidemic, with 6% of the world population suffering from the disease. However, the risk of developing type 2 diabetes can be greatly reduced by weight control, eating well and exercising before the actual manifestation of the disease. Early detection of type 2 diabetes risk before symptoms could help minimize health complications related to diabetes.
“We found that higher levels of the protein follistatin circulating in the blood predict type 2 diabetes up to nineteen years before the onset of the disease, regardless of other known risk factors, such as age, body mass index (BMI), fasting blood glucose levels, diet or physical activity.”, says Dr. Yang De Marinis, associate professor at Lund University and lead author of the study.
This discovery is based on studies that followed 5,318 people over the course of 4 to 19 years in two different locations in Sweden and Finland.
Follistatin is a protein that is mainly secreted from the liver and involved in the regulation of metabolism. The study investigated what happens to the body when follistatin in the blood circulation becomes too high. Using clinical data from the German Tübingen Diabetes Family Study and cell biology investigation, the researchers found that follistatin promotes fat breakdown from the adipose tissue, resulting in increased lipid accumulation in the liver. This in turn increases the risk of nonalcoholic fatty liver disease and type 2 diabetes.
To find out what regulates blood follistatin levels, the researchers performed genome-wide association study (GWAS) on 5,124 people from Sweden, the UK and Italy, and revealed that follistatin levels are genetically regulated by glucokinase regulatory protein (GCKR), which impact on several metabolic traits.
“This study shows that follistatin has the potential to become an important biomarker to predict future type 2 diabetes, and it also brings us one step closer to the understanding of the mechanisms behind the disease”, says Yang De Marinis.
The next step is to put the results into clinical use. An AI-based diagnostic tool using follistatin as a biomarker for type 2 diabetes is being developed through the biotech startup Lundoch Diagnostics, where Yang De Marinis is CEO. This will commercialize the tool under patent applications in global markets. The tool aims to provide a simple blood test, where results from a protein biomarker panel can be imputed in an AI-driven algorithm, and ultimately give patients a risk score to assess their risk of future type 2 diabetes.
“This discovery holds the opportunity of instituting measures to prevent type 2 diabetes from becoming established. Our research will continue towards this goal”, concludes Yang De Marinis.
Original publication
Most read news
These products might interest you

Kjel- / Dist Line by Büchi
Kjel- and Dist Line - steam distillation and Kjeldahl applications
Maximum accuracy and performance for your steam distillation and Kjeldahl applications

AZURA Purifier + LH 2.1 by KNAUER
Preparative Liquid Chromatography - New platform for more throughput
Save time and improve reproducibility during purification

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Iowa State, Ames Lab chemists discover how antiviral drugs bind to and block flu virus

Researchers engineer cells to destroy malignant tumor cells but leave the rest alone

Future Insight Prize 2023 Awarded to Khalid Salaita for Early Detection of Pandemics - Khalid Salaita awarded a research grant for the development of sensors to detect pathogens automated by DNA motors

SureSTART Vials and Well Plates | Consumables | Thermo Fisher Scientific

Sturgeon products such as caviar sold in Europe are often illegal - or not even genuine - Gene and isotope analyses show that regulations are actively being broken
